AIM:N4P

Stock Analysis Report

Executive Summary

N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom.

Snowflake

Fundamentals

Adequate balance sheet with weak fundamentals.

Share Price & News

How has N4 Pharma's share price performed over time and what events caused price changes?


Latest Share Price and Events


Market Performance


7 Day Return

3.2%

N4P

-1.2%

GB Pharmaceuticals

1.1%

GB Market


1 Year Return

-31.6%

N4P

20.5%

GB Pharmaceuticals

2.7%

GB Market

Return vs Industry: N4P underperformed the UK Pharmaceuticals industry which returned 20.5% over the past year.

Return vs Market: N4P underperformed the UK Market which returned 2.7% over the past year.


Shareholder returns

N4PIndustryMarket
7 Day3.2%-1.2%1.1%
30 Day4.8%0.9%-1.7%
90 Day-46.7%7.3%-2.7%
1 Year-31.6%-31.6%24.2%20.5%7.8%2.7%
3 Yearn/a46.9%32.5%19.3%4.7%
5 Yearn/a94.7%62.7%38.0%8.1%

Price Volatility Vs. Market

How volatile is N4 Pharma's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is N4 Pharma undervalued compared to its fair value and its price relative to the market?

2.48x

Price to Book (PB) ratio


Share Price vs. Fair Value

Undervalued: Insufficient data to calculate N4P's fair value to establish if it is undervalued.

Significantly Undervalued: Insufficient data to calculate N4P's fair value to establish if it is undervalued.


Price To Earnings Ratio

PE vs Industry: N4P is unprofitable, so we can't compare its PE Ratio to the Pharmaceuticals industry average.

PE vs Market: N4P is unprofitable, so we can't compare its PE Ratio to the UK market.


Price to Earnings Growth Ratio

Low PEG Ratio: Insufficient data to calculate N4P's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: N4P is overvalued based on its PB Ratio (2.5x) compared to the GB Pharmaceuticals industry average (2.2x).


Next Steps

  • Explore potentially undervalued companies in the Pharmaceuticals & Biotech industry.

Future Growth

How is N4 Pharma forecast to perform in the next 1 to 3 years based on estimates from 0 analysts?

28.6%

Forecasted Pharmaceuticals & Biotech industry annual growth in earnings


In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as N4 Pharma has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by SimplyWall St do have past financial data.


Next Steps

Past Performance

How has N4 Pharma performed over the past 5 years?

-1977.4%

Last years earnings growth


Earnings and Revenue History


Past Earnings Growth Analysis

Earnings Trend: N4P is unprofitable, and there is insufficient past data to establish if their past 5-year earnings growth rate was positive.

Accelerating Growth: Unable to compare N4P's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: N4P is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (24.2%).


Return on Equity

High ROE: N4P has a negative Return on Equity (-89.89%), as it is currently unprofitable.


Return on Assets

ROA vs Industry: N4P is currently unprofitable, so its Return on Assets is negative.


Return on Capital Employed

ROCE Improving: N4P is currently unprofitable, so its Return on Capital Employed is negative.


Next Steps

Financial Health

How is N4 Pharma's financial position?


Financial Position Analysis

Short Term Liabilities: N4P's short term assets (£1.4M) exceeds its short term liabilities (£104.1K)

Long Term Liabilities: N4P has no long term liabilities


Debt to Equity History and Analysis

Debt Level: N4P is debt free.

Reducing Debt: N4P had no debt 5 years ago.


Balance Sheet

Inventory Level: N4P has a low level of unsold assets or inventory.

Debt Coverage by Assets: Insufficient data to determine if N4P's debt is covered by short term assets.


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: N4P has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: N4P has less than a year of cash runway if free cash flow continues to reduce at historical rates of -47.4% each year


Next Steps

Dividend

What is N4 Pharma's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

companyn/amarketbottom25%2.0%markettop25%5.4%industryaverage3.0%forecastin3Yearsn/a

Current dividend yield vs market & industry


Stability and Growth of Payments

Notable Dividend: Unable to evaluate N4P's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.

High Dividend: Unable to evaluate N4P's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.

Stable Dividend: Insufficient data to determine if N4P's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if N4P's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of N4P's dividend in 3 years as they are not forecast to pay a notable one for the UK market.


Next Steps

Management

What is the CEO of N4 Pharma's salary, the management and board of directors tenure and is there insider trading?

0.8yrs

Average management tenure


CEO

Nigel Theobald (55yo)

2.4yrs

Tenure

0

Mr. Nigel James Theobald has been Chief Executive Officer of N4 Pharma Plc since May 3, 2017 and serves as its Director. Mr. Theobald served as the Head of Emerge Marketing Ltd., for Alltracel Pharmaceutic ...


Management Age and Tenure

0.8yrs

Average Tenure

Experienced Management: N4P's management team is not considered experienced ( 0.8 years average tenure), which suggests a new team.


Board Age and Tenure

0.4yrs

Average Tenure

53yo

Average Age

Experienced Board: N4P's board of directors are not considered experienced ( 0.4 years average tenure), which suggests a new board.


Insider Trading

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Recent Insider Transactions

BuyUK£5,98010 Apr 19
Nigel Theobald
EntityIndividual
Role
Chief Executive Officer
Founder
Shares134,686
Max PriceUK£0.044

Ownership Breakdown


Management Team

  • Nigel Theobald (55yo)

    Founder

    • Tenure: 2.4yrs
  • Andrew Leishman

    Consultant

    • Tenure: 0.8yrs
  • David Templeton

    Part-Time Executive Director & Technical Director

    • Tenure: 2.4yrs

Board Members

  • John Chiplin (60yo)

    Non-Executive Chairman

    • Tenure: 0.4yrs
  • Nigel Theobald (55yo)

    Founder

    • Tenure: 2.4yrs
  • Luke Cairns (41yo)

    Independent Non-Executive Director

    • Tenure: 0yrs
  • David Templeton

    Part-Time Executive Director & Technical Director

    • Tenure: 2.4yrs
  • Chris Britten (51yo)

    Non-Executive Director

    • Tenure: 0.4yrs

Company Information

N4 Pharma Plc's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: N4 Pharma Plc
  • Ticker: N4P
  • Exchange: AIM
  • Founded:
  • Industry: Pharmaceuticals
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: UK£3.332m
  • Shares outstanding: 101.46m
  • Website: https://www.n4pharma.com

Number of Employees


Location

  • N4 Pharma Plc
  • 60 Gracechurch Street
  • 6th Floor
  • London
  • Greater London
  • EC3V 0HR
  • United Kingdom

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
N4PAIM (London Stock Exchange AIM Market)YesOrdinary SharesGBGBPMay 2017

Biography

N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs ...


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2019/10/14 22:05
End of Day Share Price2019/10/14 00:00
Earnings2019/06/30
Annual Earnings2018/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.